Ralph Moss, Ph.D. is an independent journalistic researcher who has been investigating and writing about promising cancer treatments since 1974.
Ralph has written or edited twelve books and three film documentaries, mostly on the question of cancer research and treatment. He is a graduate of New York City public schools, New York University (BA, cum laude, Phi Beta Kappa, 1965) and Stanford University (MA, 1973, PhD, 1974, Classics).
A former science writer and assistant director of public affairs at Memorial Sloan-Kettering Cancer Center in New York (1974-1977), for over 30 years Moss has independently evaluated the claims of various cancer treatments, conventional and nonconventional. He currently directs The Moss Reports, a periodically updated library of detailed reports on 200+ varieties of cancer diagnoses. Although not a medical doctor, his articles and scientific communications have appeared in such journals as The Lancet, the Journal of the National Cancer Institute, the Journal of the American Medical Association, New Scientist, Anticancer Research, Genetic Engineering News, The Journal of Alternative and Complementary Medicine, and Integrative Cancer Therapies, of which he is Corresponding Editor.
For years he has written the monthly “War on Cancer” column for the Townsend Letter for Doctors and Patients. His op-ed “Patents Over Patients” appeared in the New York Times (4/07).
This was letter written to Dr Clement following a recent visit toour clinic.
“Dear Dr. Clement
It was a pleasure to visit the IAT Clinic in Freeport, Bahamas, last week. As you know, this was my fourth visit to your clinic since 1980. I have therefore had an opportunity to study the development and evolution of your clinic over the past three decades and because of my visits to cancer clinics around the world, am in good position to assess its international significance.
I consider the IAT clinic an important resource not only for Bahamians but for patients coming from the US and elsewhere. Over the past three decades it has offered treatments that are difficult for patients to otherwise access. For this reason cancer patients in the US and elsewhere are very grateful to have this treatment available to them as an option. I know that the 50,000 + subscribers to my weekly newsletter would be extremely upset if they knew that access to your program was in danger of being restricted in any way.
I want to emphasize that your treatments, while unusual, are not outside the realm of scientific inquiry. In particular, the late Dr. Lawrence Burton was ahead of his time in his emphasis on overcoming the “ blocking factors” in the serum of cancer patients. Various other scientists also described these factors and proposed ways of removing them. The famous scientists Karl Eric and Ingegard Hellstrom of Fred Hutchison Cancer Center in Seattle elucidated these blocking or suppressor factors in more than 50 peer reviewed articles (sample reference below). M. Rigdon Lentz, MD, and scientists at the University of California, Irvine, elucidated the nature of these blocking factors (reference below). They showed that these are soluble receptors to tumour necrosis factor (TNFR1 and TNFR2). A treatment based on this concept has now been given the CE mark in Europe and is available for use as treatment.
Your clinic is not alone either in its use of dendritic cell vaccine or other immunological treatments. These are similar to the treatments currently available in Germany at the Institute for Tumour Therapy in Duderstadt (Dr. Thomas Nesselhut) and the Eduardus Hospital in Colgne (Dr. Robert Gorter). It is extremely important that you make similar treatments available in the Western Hemisphere.
The reason that these treatments are not more freely available in the United States is because of the extremely restrictive regulatory environment towards new treatments created by the Food and Drug Administration (FDA). The reason for these regulations is as much economic as medical.”
There are some signs that FDA’s attitude towards new treatments is changing. FDA recently gave Orphan Drug status to the antievolution treatment of Dr. Stainlaw Burzynski of Houston, a treatment no less innovative and controversial than your own. There are signs that more changes will come from the new Obama administration. I hope that the Bahamain authorities will not move in an opposite direction during this time of change.
I sincerely hope that medical authorities in the Bahamas will not take any steps that restrict the access of their own citizens, to the innovative and scientific that you and your clinic have offered for the past thirty or so years. I feel so strongly about this that I am willing to come back to the Bahamas at your request to meet with any relevant authorities to explain the basis for this opinion.
Feel free to use this letter in whatever way you see fit.
Ralph W. Moss, PhD.
Gatanga T, Hwang CD, Kohr W, CappuciniF, Lucci JA 3rd, JeffesEW, Lentz R, Tomich J, Yamamoto RS, Granger GA. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumour necrosis factor and lymphotoxin obtained fromhe serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA. 1990 Nov; 87(22):8781-4.
Hellstrom KE, Hellstrom I, Sydney HW Jr, Balint JP, Jones FR, Blockin (suppressor) factors, immune complexes, and extracorporeal immunoadsorption in tumour immunity. Contemp Top Immunobiol. 1985; 15:213-38. Review
Stiglitz, Joseph. Give prizes not patents. New Scientist. Sept. 16, 2006.